Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine 2% for Preventing Graft Rejection
NCT02206789Unknown
- Sponsor
- Aravind Eye Care System
- Start
- Feb 2012
- Primary completion
- Feb 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of cyclosporine in corneal graft rejection (CGR) (4 arms), sponsored by Aravind Eye Care System. Primary endpoint: Incidence of graft rejection at 5 years. Status: unknown.
02
Drugs
cyclosporine
03
Conditions
corneal graft rejection (CGR)
Beyond the preview
Go deeper on NCT02206789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02206789.